Protein Biomarkers for Breast Cancer
Biotech Support Group reported a new research report which highlights their proteomic sample preparation technology as an initial enrichment step to the Array Bridge (St. Louis, MO) Protein Elution Plate (PEP). The combined methods support functional proteomic profiling of breast cancer sera.
In this study, a functional proteomics technology was used to systematically monitor metabolic enzyme and protease activities from resolved serum proteins produced by a modified 2-D gel separation and subsequent Protein Elution Plate, a method collectively called PEP. AlbuVoid was used to remove Albumin and enrich the low abundance serum proteome.
The article states “The most dramatic difference for enzyme activity detection in using the AlbuVoid™ for serum protein enrichment was demonstrated. Compared with the direct serum proteinase measurement, both the levels and species of proteases were increased significantly in the enriched serum sample. Protease activity in the direct serum analysis suggested that the protease levels in the serum were below the detection threshold of protease activity ,and it is necessary to use AlbuVoid to enrich these low level proteases to bring them to a high enough level to be detected.”
Both qualitative and quantitative differences in the metabolic enzyme and protease activity were detected between breast cancer patient and control group, providing excellent biomarker candidates for breast cancer diagnosis and drug development.
“We are very pleased to see that AlbuVoid provided the enrichment necessary to uncover biomarker candidates for cancer using the PEP platform. A key feature in all of our products is to not only separate proteomes but to retain the functional features of proteins after separations. This is important as protein conformations is highly variable, each conformation contributes to its own unique functional activity. AlbuVoid enrichment followed by PEP can profile these functional activities” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.
Wang, D. L., Xiao, C., Fu, G., Wang, X., & Li, L. (2017). Identification of potential serum biomarkers for breast cancer using a functional proteomics technology. Biomarker Research, 5(1). doi:10.1186/s40364-017-0092-9
This article has been republished from materials provided by Biotech Support Group. Note: material may have been edited for length and content. For further information, please contact the cited source.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBO Workshop: Integrating Systems Biology: From Networks to Mechanisms to Models
Apr 15 - Apr 17, 2018
EMBL Course: Introduction to Metabolomics Analysis
Mar 20 - Mar 23, 2018